Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines

Liu, Xue-En; Wushouer, Fuerhati; Gou, Aili; Kuerban, Mahemuti; Li, Xinlan; Sun, Yubo; Zhang, Jiamin; Liu, Yan; Li, Jie; Zhang, Hui

doi:10.4161/hv.24366

Cited by 10 publications

(2 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Well-tolerated, highly immunogenic and effective HAV inactivated and live vaccines are available [1, 49–53]. Contrary to the belief that the immune response to an inactivated vaccine is mostly humoral with little or no cellular immunity, protein-based inactivated HAV vaccines have been able to demonstrate both humoral and cell-mediated immune responses [54, 55].…”

Section: Discussionmentioning

confidence: 99%

Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent

et al. 2019

View full text Add to dashboard Cite

Hepatitis A, an acute inflammatory liver disease caused by hepatitis A virus (HAV) infection from close contact with infected people, is highly endemic in the Indian subcontinent. Due to poor sanitary conditions, most of the population is exposed to the virus in childhood. At this age, the disease is asymptomatic and provides lifelong protection against the disease. Due to rapid socioeconomic development in some areas, however, pockets of the population are reaching adolescence/ adulthood without prior exposure to the virus and are thus susceptible to infection. At these ages, infection carries a higher risk of symptomatic disease and complications including mortality. This review of epidemiology and burden of disease studies in the Indian subcontinent, published since 2005, shows increasing evidence of a shift from high to intermediate endemicity in high-income-typically urban-populations. The prevalence of anti-HAV antibodies (previously reported at [ 90%) is lower now in adolescents and young adults (e.g., around 80% in Bangladesh and 55% in 5-15 years in India). As a result, HAV is responsible for more acute viral hepatitis predominantly in this age group (e.g., [ 15 years: 3.

show abstract

Section: Discussionmentioning

confidence: 99%

Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent

et al. 2019

View full text Add to dashboard Cite

show abstract

“…14 Another study compared the one-year antibody persistency between Healive Ò and 3 kinds of live attenuated vaccines in children. 15 At 12 month, no significant differences were observed in seroconversion rates among the 4 groups(range: 92.8% -96.6%; P> 0.05); however, the GMC of Healive Ò was lower than that in the attenuated vaccine B and C groups (112.7 vs. 203.3, 212.8mIU/ml, p < 0.05) and similar to the attenuated vaccine A group (112.7 vs. 135.8 mIU/ml, P > 0.05). And all the above studies showed similar safety profile between Healive Ò and live attenuated HA vaccine.…”

Section: Discussionmentioning

confidence: 99%

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Zhang

Zhu

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In China, both inactivated hepatitis A (HA) vaccine and live attenuated HA vaccine are available. We conducted a trial to evaluate 5-year immune persistence induced by one dose of inactivated or live attenuated HA vaccines in children. Subjects with no HA vaccination history had randomly received one dose of inactivated or live attenuated HA vaccine at 18-60 months of age. Anti-HAV antibody concentrations were measured before vaccination and at the first, second, and fifth year after vaccination. Suspected cases of hepatitis A were monitored during the study period. A total of 332 subjects were enrolled and 182 provided evaluable serum samples at all planned time points. seropositive rate at 5 y was 85.9% in the inactivated HA vaccine group and 90.7% in the live attenuated HA vaccine group. GMCs were 76.3% mIU/ml (95% CI: 61.7 - 94.4) and 66.8mIU/ml (95% CI: 57.8 - 77.3), respectively. No significant difference in antibody persistence between 2 groups was found. No clinical hepatitis A case was reported. A single dose of an inactivated or live attenuated HA vaccine at 18-60 months of age resulted in high HAV seropositive rate and anti-HAV antibody concentrations that lasted for at least 5 y.

show abstract

Prevention of Hepatitis A

Shouval

2019

Viral Hepatitis in Children

View full text Add to dashboard Cite

Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines

Cited by 10 publications

References 15 publications

Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent

Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent

Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine

Prevention of Hepatitis A

Contact Info

Product

Resources

About